This study uses institutional theory to explore the driving force for internationalization of firms in emerging economies. It posits that the internationalization practices of firms are driven not only by efficiency consideration, but also by the desire to conform to institutional isomorphic pressures exerted by the social environment. The impact of three types of institutional isomorphic pressures -coercive pressure, mimetic pressure and normative pressure -on the intensity of internationalization is investigated. Analysis using survey data collected from 174 Chinese firms shows that all three institutional pressures have positive and significant effects on the intensity of internationalization. We also examine the interaction between institutional pressure and firm capability. Results suggest that firm capabilities enhance the effect of coercive pressure on internationalization, and weaken the effect of normative pressure on internationalization.

Purpose This study aims to examine the dual effects of home country institutional forces (i.e. institutional support and institutional constraints) on the internationalization of private firms in emerging markets. By doing so, this study aims to examine the applicability of the two seemingly paradoxical views (i.e. the governmental promotion view and the institutional escapism view) in explaining private firms’ internationalization. Further, this study investigates how the effect of the home country institutional environment on firms’ internationalization is contingent upon firm characteristics. Design/methodology/approach A sample of Chinese private firms is used to examine the effect of home country institutions on internationalization. Findings Empirical findings suggest that both institutional support and institutional constraints promote the internationalization of private firms in emerging markets. Moreover, it is found that firm resources strengthen the effect of government support on internationalization. It is also found that firms’ business ties strengthen the effect of institutional constraint on internationalization, whereas firms’ political ties weaken the effect of institutional constraints on internationalization. Originality/value By adopting an integrated and comprehensive investigation of the dual effects of home country institutional environment in emerging markets on internationalization, this study provides evidence to the applicability of the two competing views (i.e. the governmental promotion view and the institutional escapism view) in relation to home country institutional effects on internationalization. In addition, this study examines how institutional effects vary across firms with different resources and social ties, thus extends understandings of the boundary conditions of the two institutional effects.

Background: Camrelizumab, which was launched in China on May 29, 2019, is a humanized anti-Programmed cell Death-1 (PD-1) antibody. It is used for the treatment of complicated or refractory classic Hodgkin's lymphoma with at least second-line chemotherapy. On March 4, 2020, camrelizumab was approved as second-line drug in China for the treatment of patients with advanced hepatocellular carcinoma. Currently, camrelizumab is undergoing clinical research in multiple tumor fields, including advanced solid tumors such as liver cancer, gastric cancer, esophageal cancer, and lung cancer, and all have shown clinical efficacy. Objective: This review mainly describes the preclinical studies of camrelizumab and its efficacy and safety in clinical studies in various tumors. Methods: A comprehensive literature search was conducted on the basic research and clinical trials of camrelizumab to determine its pharmacology, toxicology, pharmacokinetic properties and current clinical research status. And we analyzed the difference between Karelizumab and other PD-1 antibodies. Results: The results of the pre-clinical studies showed that camrelizumab bond to PD-1 receptor and had stable anti-tumor activity in a dose-dependent manner. Clinical studies have shown that camrelizumab has therapeutic effects on a variety of tumors, and it is expected to become a routine drug in the field of tumor therapy in the future. The incidence of adverse reactions with camrelizumab is low and most of them are mild, reversible and predictable. Conclusion: This review summarizes the current status of preclinical and clinical studies of camrelizumab. Current research data confirm that camrelizumab alone or in combination with other drugs have shown significant anti-cancer activity and lower incidence of adverse reactions, which may be related to its patent. However, further studies are still needed to verify the application potential of camrelizumab in a variety of tumors.

A flavanoid fraction (FF) from Drynaria fortunei, was investigated to see if it has the protective and ameliorative effects against gentamicin (GM) ototoxicity in guinea pigs (n = 36). Eleven (GM-group) animals received GM 100 mg/kg/day. Eleven (GMFF-group) animals received the same dose of GM but 2 days prior were dosed with FF (10 mg/kg/day) for 2 weeks. Seven (S-group) animals received saline and seven (FF-group) animals received the same dose of FF as the GMFF-group. The thresholds of tone-burst auditory evoked response (ABR) at 2 k, 8 k, and 32 k Hz were determined to be as follows: GM-group: 90 dB, 92 dB and 72 dB, GMFF-group: 30 dB, 37 dB and 38 dB, FF-group: 28 dB, 25 dB and 29 dB, S-group: 30 dB, 28 dB and 39 dB. The GM-group had a significantly higher hearing threshold than the other groups (p < 0.05). The GMFF- and FF-groups had hearing thresholds similar to the S-groups (p > 0.1). Repair of damaged hair cells was observed histologically. The percentage of the damaged outer hair cells (OHC) and inner hair cells (IHC) were determined to be as follows: GM-group: 43% and 20%, GMFF-group: 20% and 2%, FF-group: 9% and 2% and S-group: 4% and 1%. The GMFF-group showed less damage to the OHC (p > 0.05) and significantly less damage to the IHC (p < 0.05) than the GM-group. FF did not change the antimicrobial activity of GM and it did not show any intrinsic antibacterial effect. FF did not affect the kinetics of GM during the course of the experiment.

The flavonoid fraction (FF) from Drynaria fortunei was investigated to determine its biological activity expression in three acute renal failure animal models. Guinea pigs received 100 mg/kg of gentamicin (GM group), 100 mg/kg of GM plus 10 mg/kg of FF (GMFF group), 10 mg/kg of FF (FF group) or saline (saline group) intramuscularly for 14 days. The blood urea nitrogen (BUN) and creatinine levels were found to be significantly higher in the GM group (22.70+/-3.84 mg/dL, 0.68+/-0.05 mg/dL) than in the GMFF group (17.10+/-1.04 mg/dL, 0.58+/-0.09 mg/dL), the FF group (17.40+/-1.01 mg/dL, 0.49+/-0.20 mg/dL) and the saline group (17.50+/-1.22 mg/dL, 0.50+/-0.02 mg/dL). Mice were treated once with 6 mg/kg of mercuric chloride, followed by 10 mg/kg of FF or saline. On days 3, 4 and 5, BUN and creatinine levels were found to be significantly higher in the HgCl2-saline group (74.00+/-39.20 mg/dL, 59.30+/-31.20 mg/dL, 74.00+/-37.30 mg/dL and 0.53+/-0.17 mg/dL, 0.48+/-0.15 mg/dL 0.33+/-0.15 mg/dL) than in the HgCl2-FF group (19.50+/-4.90 mg/dL, 43.00+/-26.30 mg/dL, 38.50+/-13.80 mg/dL and 0.23+/-0.05 mg/dL, 0.30+/-0.12 mg/dL, 0.15+/-0.06 mg/dL).After surgery for 5/6-nephrectomy, ten mice received FF at a dose of 10 mg/kg/day and eight received saline for 42 days. The saline group survived for 12-62 days and the FF group survived for 20-320 days. The FF group had a significantly longer survival time than the saline group (p<0.05). Regeneration of kidney tubular cells and significantly enlarged convoluted tubules were noted in the pathology study of the FF group. In conclusion, the present study suggests that FF prevents nephrotoxicity, improves kidney function and promotes kidney primary epithelial tubular cell regeneration.